^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | saracatinib (AZD0530) (Src kinase inhibitor, FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations....Both IDHm ICC lines also demonstrated outlier sensitivity to saracatinib.
DOI:
10.1158/2159-8290.CD-15-1442
